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Peripheral blood B lymphocytes derived from patients with
idiopathic pulmonary arterial hypertension express a different
RNA pattern compared with healthy controls: a cross sectional
study
Abstract
BACKGROUND: Idiopathic pulmonary arterial hypertension (IPAH) is a progressive and still incurable
disease. Research of IPAH-pathogenesis is complicated by the lack of a direct access to the involved
tissue, the human pulmonary vasculature. Various auto-antibodies have been described in the blood of
patients with IPAH. The purpose of the present work was therefore to comparatively analyze peripheral
blood B lymphocyte RNA expression characteristics in IPAH and healthy controls. METHODS:
Patients were diagnosed having IPAH according to WHO (mean pulmonary arterial pressure > or = 25
mmHg, pulmonary capillary occlusion pressure < or = 15 mmHg, absence of another explaining
disease). Peripheral blood B-lymphocytes of patients and controls were immediately separated by
density gradient centrifugation and magnetic beads for CD19. RNA was thereafter extracted and
analyzed by the use of a high sensitivity gene chip (Affymetrix HG-U133-Plus2) able to analyze 47000
transcripts and variants of human genes. The array data were analyzed by two different softwares, and
up-and down-regulations were defined as at least 1.3 fold with standard deviations smaller than
fold-changes. RESULTS: Highly purified B-cells of 5 patients with IPAH (mean pulmonary artery
pressure 51 +/- 13 mmHg) and 5 controls were analyzed. Using the two different analyzing methods we
found 225 respectively 128 transcripts which were up-regulated (1.3-30.7 fold) in IPAH compared with
healthy controls. Combining both methods, there were 33 overlapping up-regulated transcripts and no
down-regulated B-cell transcripts. CONCLUSION: Patients with IPAH have a distinct RNA expression
profile of their peripheral blood B-lymphocytes compared to healthy controls with some clearly
up-regulated genes. Our finding suggests that in IPAH patients B cells are activated.
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Abstract
Background: Idiopathic pulmonary arterial hypertension (IPAH) is a progressive and still incurable
disease. Research of IPAH-pathogenesis is complicated by the lack of a direct access to the involved
tissue, the human pulmonary vasculature. Various auto-antibodies have been described in the blood
of patients with IPAH. The purpose of the present work was therefore to comparatively analyze
peripheral blood B lymphocyte RNA expression characteristics in IPAH and healthy controls.
Methods: Patients were diagnosed having IPAH according to WHO (mean pulmonary arterial
pressure ≥ 25 mmHg, pulmonary capillary occlusion pressure ≤ 15 mmHg, absence of another
explaining disease). Peripheral blood B-lymphocytes of patients and controls were immediately
separated by density gradient centrifugation and magnetic beads for CD19. RNA was thereafter
extracted and analyzed by the use of a high sensitivity gene chip (Affymetrix HG-U133-Plus2) able
to analyze 47000 transcripts and variants of human genes. The array data were analyzed by two
different softwares, and up-and down-regulations were defined as at least 1.3 fold with standard
deviations smaller than fold-changes.
Results: Highly purified B-cells of 5 patients with IPAH (mean pulmonary artery pressure 51 ± 13
mmHg) and 5 controls were analyzed. Using the two different analyzing methods we found 225
respectively 128 transcripts which were up-regulated (1.3–30.7 fold) in IPAH compared with
healthy controls. Combining both methods, there were 33 overlapping up-regulated transcripts and
no down-regulated B-cell transcripts.
Conclusion: Patients with IPAH have a distinct RNA expression profile of their peripheral blood
B-lymphocytes compared to healthy controls with some clearly up-regulated genes. Our finding
suggests that in IPAH patients B cells are activated.
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Idiopathic pulmonary arterial hypertension (IPAH) is his-
topathologically characterized by endothelial cell prolifer-
ation and formation of plexiform lesions. Plexiform
lesions are often found to be surrounded by immune
cells, which have been identified as B- and T-lymphocytes,
macrophages and mast cells [1,2]. The possible pathoge-
netic role of the immune system in IPAH is further sup-
ported by the close association between various immune
disorders and pulmonary arterial hypertension and the
frequent finding of autoimmune antibodies and altered
cytokine status in serum of IPAH patients [3,4]. B-lym-
phocytes (B-cells) are fundamental for the humoral
immune response due to their potential to differentiate
into antibody-producing plasma B-cells. But B-cells also
play a crucial role in cell-mediated immune regulation
through antigen presentation, production of various
cytokines, differentiation of T effector cells and collabora-
tion with antigen-presenting dendritic cells and lymphoid
organogenesis. Antibodies directed against pulmonary
endothelial cells have been found in IPAH[5]. The gener-
ation of these autoantibodies from mature B-cells might
be explained by a different RNA expression profile
between B-cells of patients with IPAH and healthy control
cells and thus might present a different translational func-
tionality. Moreover, the differential RNA-pattern of B-cells
in IPAH might provide helpful information to elucidate
the pathogenetic role of the immune system in IPAH and
might be of diagnostic value in the early detection of the
disease.
Methods
Subjects
Patients were diagnosed with IPAH according to WHO if
the mean pulmonary artery pressure was ≥ 25 mmHg by
right heart catheterization and an extensive clinical work-
up did not reveal other conditions responsible for pulmo-
nary arterial hypertension[6]. Patients and healthy volun-
teers gave their written informed consent and the study
was approved by the local institutional review board
(Colorado Multiple Institution Review Board [COMIRB]).
Blood collection and B cell separation and RNA-extraction
10 ml of peripheral blood was collected in tubes contain-
ing ethylenediamineteraacetic acid and samples were
processed within 30–60' after blood drawn under careful
and frequent decontamination of the working space and
all materials needed (RNAseZAP, Ambion, TX, US, Cat
#9790). The blood was diluted in three volumes of phos-
phate-buffered saline + 2-mM ethylenediamineteraacetic
acid + 0.5% bovine serum albumin. The peripheral blood
mononuclear cell (PBMC) layer was isolated via density
gradient centrifugation (Histopaque 1077, Sigma-Aldrich,
St. Louis, USA), at 1200 rpm for 30 min. B cells were mag-
netically separated from PBMC's using MACS anti-CD19
micro beads (Miltenyi Biotec, Bergisch-Gladbach, Ger-
many). Purity of the B-cell separation was assessed by
flow-cytometry after staining 100'000 cells with fluores-
cently labelled monoclonal antibody against CD 19 (anti-
CD19-APC respectively FACS Calibur, BD Biosciences,
NY, USA). B-cell pellets were dissolved in 1 ml of TRI rea-
gent (Ambion, Tx, US, Cat) and stored at -80°C until RNA
extraction.
All frozen B cells samples were simultaneously defrosted
on ice. After thawing, the RNA was extracted using RiboP-
ureTM-Kit (Ambion, Tx, US Cat # 1924) according to the
manufacture's instruction and stored at -20°C until RNA
microarray was performed.
Microarray data generation
RNA quality assessment, sample preparation, reverse tran-
scription, labeling, high-density oligonucleotide array
hybridization, scanning and data analysis were performed
according to standard practice [7-10]. Samples were ana-
lyzed by the use of the Affymetrix HG-U133-Plus2 gene
chip, which is able to analyze 47,000 transcripts and vari-
ants, including 38,500 well-characterized human genes
due to its high resolution (Affymetrix, CA, US). Fluores-
cence intensities were quantified using the affymetrix
Microarray Analysis Suite 5.0 (MAS5) and Robust Multi-
chip Analysis (RMA) statistical algorithm with default
parameters for the array type used in this study (Affyme-
trix HG-U133-Plus2, CA, US).
Data analysis and statistics
Detailed protocols for data analysis of Affymetrix microar-
rays and extensive documentation of the sensitivity and
quantitative aspects of the method have been
described[11]. In brief, the array data were analyzed by
GeneChip® Operating Software (GCOS, Affymetrix, CA,
US) and genesprings software (GSS, Agilent Technologies,
CA, US). Both softwares are able to statistically analyze
quantitative signal expression levels retrieved from the
Affymetrix microarray with GCOS mainly used for com-
parison of expression profiles between single patients
across groups and GSS used to compare differential
expression profiles between groups (e.g. healthy vs dis-
eased). The raw data from array scans were averaged
across all gene probes on each array by MAS5 and RMA,
two different mathematical algorithms to process, back-
ground-correct and normalize raw data from microarray
gene chips, thereafter, a scaling factor was applied to bring
the average intensity for all probes on the array to 500. For
further normalization of the raw data all signal values
were log transformed (log base 2), values below 0.01 were
set to 0.01, each measurement was divided by the 50.0th
percentile of all measurements in that sample and each
gene was divided by the median of its measurements in all
samples. To define up- and down-regulated genes in IPAHPage 2 of 7
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or marginal in all 5 IPAH samples (for up-regulated
genes) or not-present (for down-regulated genes) in com-
parison with controls were selected as first filter technique
by GSS. As second filter, up- and down regulated genes
were selected if they were present or marginal in 4 of the
5 IPAH versus control samples and if a statistical differ-
ence was present between IPAH and control values (Stu-
dent's t-test, p-value cut-off 0.05). By using GSS, all genes
with normalized data values >1.3 fold higher respectively
lower than in the other groups were selected. By our sec-
ond software, the GCOS, we select all genes which were
up- or down-regulated in IPAH vs. controls in at least 15
of the possible 25 comparisons with a fold change (FC)
greater than the calculated standard deviation for each
gene.
Results
B-cells from five Caucasian patients with severe IPAH
(mean age 46 ± 8.1 years, 3 females, mean pulmonary
artery pressure 51 ± 13 mmHg, mean cardiac index 2.2 ±
0.2 ml/min/m-2) and five healthy Caucasian controls
(mean age 47 ± 8.7 years, 3 females) were analyzed. Four
of the patients were on intravenous epoprostenol therapy.
The B-cell purity checked by flow cytometry detecting flu-
orescently labeled CD-19 was > 97%. B-cell RNA and raw
data quality was good as per the specialist in the Gene-
Chip processing core facility of the university of Colorado
Health Science Centre (UCHSC). Using GCOS we found
225 genes which were at least 1.3 fold up-regulated in
IPAH vs. controls (1.3 – 30.7 fold, SD < FC). Using GSS
we found 128 up-regulated genes (1.3–178 fold). Com-
bining analysis by both methods, we found overlap of 33
up-regulated genes (table 1, figure 1). Of interest, many of
the up-regulated genes belong to biological processes
involved in inflammation and immune responses, sug-
gesting the activation of B cells in patients with IPAH In
contrast, we found no down-regulated genes.
Discussion
In the present study we comparatively investigated B-cell
RNA expression profiles in patients with IPAH and
healthy controls. We hereby found that IPAH patients
slightly differed from healthy controls with some clearly
up-regulated genes consistently found by two different
analysis methods.
IPAH is a devastating and progressive condition of
unknown etiology affecting the pulmonary circulation
with a dismal prognosis [6]. Research on the pathobiol-
ogy of IPAH on the molecular level is limited by a lack of
a direct and early access to the site of pathology, the
human lung. One research strategy therefore lays in the
analysis of easily obtainable peripheral blood samples
from IPAH patients in order to retrieve both information
on possible underlying disease mechanisms and potential
diagnostic tools. Recently, a strategy of assessing RNA-
expression profiles of peripheral blood mononuclear cells
by microarrays was introduced and shown to be able to
differentiate variously classified pulmonary arterial hyper-
tension patients and healthy controls[12]. In this work we
focus this strategy based on microarray technology
towards peripheral blood B-cells, based on the hypothesis
to find specifically differential RNA expression profiles in
a disease where various auto-antibodies have been found
in the peripheral blood[4,5,13]. Indeed we found a
slightly distinct RNA-expression profile with some up-reg-
ulated genes on the transcript level. At this point however,
we can only speculate about the biological significance of
these up-regulated genes and will in the following discuss
some of them with potential value in respect to the patho-
genesis of IPAH (table 1). Strikingly, many of the up-reg-
ulated transcripts are involved in inflammatory
mechanisms, host defense or endothelial function.
Human defensins are small cationic peptides involved in
various biological processes associated primarily with
defensive and regulatory responses to infections by path-
ological agents but they also have immunoregulatory
properties, associated with their ability to bind and acti-
vate the G(i)-protein-coupled seven-transmembrane
receptors and are chemoattractants for dendritic cells and
memory T cells[14]. Increased airway epithelial defensin
concentrations were found in association with various
pulmonary infections[15] and plasma alpha-defensin
concentrations were found increased in pulmonary sar-
coidosis, a disease often associated with an until now uni-
dentified infectious agent [16]. It is increasingly
recognized that a deregulated immune system plays a
pathogenetic role in IPAH[17,18], although a clear idea
about an initial trigger and potentially involved pathways
is still lacking. The herein found clear up-regulation of the
B-cell RNA encoding for defensin alpha 1 in IPAH may
indicate that a hitherto unknown infectious trigger may be
pathogenetically involved. Other herein-found up-regu-
lated transcripts associated with inflammatory mecha-
nisms are sequences encoding for the major
histocompatibility complex class II (HLA_DQB1 and 2),
ribonucleotide reductase M2 polypeptides (which confer
resistance to hydroxyurea in lymphoblastic and other
tumor cell lines [19] and members of the tumor necrosis
factor superfamily.
Other herein found up-regulated transcripts in B-cells of
IPAH patients are involved in vessel biology, vasomotor
regulation, angiogenesis or cell proliferation. Tumor-like
proliferating endothelial and smooth muscle cell accumu-
lating in the so called plexiform lesions are the corner-
stone of histologic finding in IPAH. The S-100 calcium
binding protein is not only a marker of tumor cell lines
(e.g. melanoma or neurogenous tumors), it is alsoPage 3 of 7
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Gene Name Fold Change Description Gene Symbol GO Biological Process Description
205033_s_at 30.76 defensin, alpha 1, myeloid-related 
sequence
DEFA1 /// DEFA3 xenobiotic metabolism /// response to virus /// defense 
response to bacteria /// defense response to fungi /// 
defense response /// response to pest, pathogen or 
parasite
204351_at 15.05 S100 calcium binding protein P S100P endothelial cell migration
232629_at 10.03 prokineticin 2 PROK2 activation of MAPK activity /// angiogenesis /// anti-
apoptosis /// chemotaxis /// inflammatory response /// 
elevation of cytosolic calcium ion concentration /// 
neuropeptide signaling pathway /// spermatogenesis /// 
cell proliferation /// sensory percept
202917_s_at 5.678 S100 calcium binding protein A8 
(calgranulin A)
S100A8 inflammatory response
211654_x_at 5.479 major histocompatibility complex, 
class II, DQ beta 1
HLA-DQB1 immune response /// immune response /// antigen 
presentation, exogenous antigen /// antigen processing, 
exogenous antigen via MHC class II
209773_s_at 5.435 ribonucleotide reductase M2 
polypeptide
RRM2 DNA replication /// deoxyribonucleoside diphosphate 
metabolism /// DNA replication
220005_at 5.189 G protein-coupled receptor 86 P2RY13 signal transduction /// G-protein coupled receptor 
protein signaling pathway
225987_at 4.787 likely ortholog of mouse tumor 
necrosis-alpha-induced adipose-
related protein
STEAP4 fat cell differentiation /// electron transport
209773_s_at 5.435 ribonucleotide reductase M2 
polypeptide
RRM2 DNA replication /// deoxyribonucleoside diphosphate 
metabolism /// DNA replication
220005_at 5.189 G protein-coupled receptor 86 P2RY13 signal transduction /// G-protein coupled receptor 
protein signaling pathway
225987_at 4.787 likely ortholog of mouse tumor 
necrosis-alpha-induced adipose-
related protein
STEAP4 fat cell differentiation /// electron transport
212999_x_at 4.322 major histocompatibility complex, 
class II, DQ beta 1
HLA-DQB1 immune response /// immune response /// antigen 
presentation, exogenous antigen /// antigen processing, 
exogenous antigen via MHC class II
220167_s_at 3.448 TP53TG3 protein TP53TG3 ---
223204_at 3.429 hypothetical protein 
DKFZp434L142
DKFZp434L142 ---
213975_s_at 2.807 lysozyme (renal amyloidosis) LYZ /// LILRB1 carbohydrate metabolism /// cell wall catabolism /// 
cytolysis /// defense response to bacteria /// immune 
response /// response to virus /// tRNA aminoacylation 
for protein translation
209514_s_at 2.779 RAB27A, member RAS oncogene 
family
RAB27A intracellular protein transport /// small GTPase mediated 
signal transduction /// protein transport
228898_s_at 2.13 similar to putative NADH 
oxidoreductase complex I subunit 
homolog.
SMARCB1 chromatin remodeling /// transcription /// regulation of 
transcription from RNA polymerase II promoter /// cell 
cycle /// DNA integration /// negative regulation of 
progression through cell cycle /// retroviral genome 
replication /// regulation of transcription
201310_s_at 2.039 chromosome 5 open reading 
frame 13
C5orf13 ---
227724_at 1.956 hypothetical gene supported by 
AK091744
LOC439987 ---
208704_x_at 1.92 amyloid beta (A4) precursor-like 
protein 2
APLP2 G-protein coupled receptor protein signaling pathway
222688_at 1.916 yf40c04.s1 Soares fetal liver spleen 
1NFLS Homo sapiens cDNA 
clone IMAGE:129318 3', mRNA 
sequence.
PHCA protein biosynthesis /// ceramide metabolism
214864_s_at 1.852 glyoxylate reductase/
hydroxypyruvate reductase
GRHPR L-serine biosynthesis /// excretion /// metabolism /// 
metabolism
230126_s_at 1.774 KIAA0876 protein JMJD2B regulation of transcription, DNA-dependent
207426_s_at 1.774 tumor necrosis factor (ligand) 
superfamily, member 4 (tax-
transcriptionally activated 
glycoprotein 1, 34kDa)
TNFSF4 immune response /// signal transduction /// cell-cell 
signaling /// positive regulation of cell proliferationPage 4 of 7
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class II, DQ beta 2
HLA-DQB2 immune response /// immune response /// antigen 
presentation, exogenous antigen /// antigen processing, 
exogenous antigen via MHC class II
212495_at 1.745 KIAA0876 protein JMJD2B regulation of transcription, DNA-dependent
221581_s_at 1.676 Williams-Beuren syndrome 
chromosome region 5
LAT2 intracellular signaling cascade /// calcium-mediated 
signaling /// immune response /// mast cell degranulation /
// B cell activation
208248_x_at 1.672 amyloid beta (A4) precursor-like 
protein 2
APLP2 G-protein coupled receptor protein signaling pathway
226456_at 1.66 hypothetical protein MGC24665 MGC24665 ---
208703_s_at 1.651 amyloid beta (A4) precursor-like 
protein 2
APLP2 G-protein coupled receptor protein signaling pathway
212496_s_at 1.625 KIAA0876 protein JMJD2B regulation of transcription, DNA-dependent
223445_at 1.588 dystrobrevin binding protein 1 DTNBP1 organelle organization and biogenesis /// sensory 
perception /// visual perception /// response to stimulus
225593_at 1.578 U7 snRNP-specific Sm-like protein 
LSM10
LSM10 nuclear mRNA splicing, via spliceosome /// mRNA 
processing
223361_at 1.537 similar to HSPC280 C6orf115 ---
224948_at 1.477 mitochondrial ribosomal protein 
S24
MRPS24 ---
Table 1: Up-regulated genes in IPAH vs. controls: at least 1.3 fold up-regulated in GCOS and GSS (Continued)Page 5 of 7
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Cluster dendrogram of up-regulated genes in 5 patients with idiopathic pulmonary arterial hypertension (lower rows, PAH-
number) and 5 healthy controls (upper rows, ctrl-number). The color-scale goes from blue (not up-regulated) to red (highly 
up-regulated) as indicated (scale on the right).
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Prokineticins, herein found 10-fold up-regulated in IPAH
patient B-cells vs. healthy controls, are multifunctional
secreted proteins able to activate distinct endogenous G-
protein coupled pathways, thereby stimulating Ca2+
mobilization and cAMP accumulation[22]. Prokineticins
also play a role in circadian rhythms [23], they also seem
to have different pathophysiological roles in various
endothelial cell systems[24,25]. Another potentially inter-
esting herein found up-regulated transcript encodes for
the purinergic receptor P2Y (or G-protein coupled recep-
tor 86), which has not only been described playing a role
in some leukemias and cancers[26,27], but has recently
been implicated in the risk of atherothrombosis, namely
ischemic stroke, myocardial infarction and venous throm-
boembolism[28]. This protein deserves being evaluated
by future research in IPAH, the intrinsic illness of the pul-
monary vasculature where microthrombosis is one of the
key pathologic features. Interestingly, also transcripts
encoding for different types of amyloid beta precursor-
like proteins are herein consistently found up-regulated in
IPAH. Amyloid beta proteins are important initiating
molecules in the pathogenesis of Alzheimer's disease[29].
But the beta amyloid precursor protein is also highly
expressed in the endothelium on neoforming vessels sug-
gesting that it may play a role during angiogenesis[30]. An
association between pulmonary arterial hypertension and
Alzheimer's disease has not been described so far; how-
ever, autopsy studies reveal that venous thrombosis and
atherosclerotic cardiovascular diseases are highly com-
mon comorbidities in Alzheimer patients, so the question
of a potential association with pulmonary vascular disease
as well may merit evaluation in light of our findings[31].
Our study has several limitations: our sample size investi-
gating 5 patients and controls each is rather small, how-
ever, it included a broad and costly gene chip in order to
retrieve the highest amount of possibly involved genes.
Another limitation of our study is that we do not know if
changes in the peripheral blood B-cell RNA expression
profiles found are related to, cause or consequence of the
pressure elevation found in the pulmonary vasculature.
Furthermore, therapy might influence gene expression
profiles in general. Preliminary data of the present study
however could not observe such effect between B-cells
from patients with and without epoprostenol treatment.
The study of peripheral blood B-cell RNA expression pro-
files has further intrinsic limitation, as we do not know
whether similar up-regulated transcripts would be found
in the pulmonary vasculature itself. Finally, the biological
significance of the genes detected has not been investi-
gated by functional analyses. These issues will be
addressed by subsequent studies. Despite these limita-
tions, our studies suggest that B cells are activated in
patient with IPAH. We strongly believe that the results
present herein contribute significantly to our understand-
ing of the pathogenesis of IPHA and thus might help to
find new treatment strategies for this still incurable, dev-
astating disease.
Conclusion
We found that patients with IPAH express a distinct RNA
expression profile in their peripheral blood B-lym-
phocytes that clearly suggests activation of B cells when
compared with healthy controls The up-regulated tran-
scripts herein described may help to direct future research
on the pathogenesis of pulmonary arterial hypertension.
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